LIVN Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -103.3% compared to LivaNova PLC's net margin of -126.59%. LivaNova PLC's return on equity of -18.12% beat Retractable Technologies's return on equity of -26.39%.

LivaNova PLC has a consensus price target of $61.36, signalling upside risk potential of 46.52%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that LivaNova PLC has higher upside potential than Retractable Technologies, analysts believe LivaNova PLC is more attractive than Retractable Technologies.

LivaNova PLC has a beta of 0.842, which suggesting that the stock is 15.825% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.650, suggesting its more volatile than the S&P 500 by 64.995%.

LivaNova PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova PLC pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

LivaNova PLC quarterly revenues are $316.9M, which are larger than Retractable Technologies quarterly revenues of $8.3M. LivaNova PLC's net income of -$327.3M is lower than Retractable Technologies's net income of -$10.5M. Notably, LivaNova PLC's price-to-earnings ratio is 38.16x while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova PLC is 1.79x versus 0.58x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -103.3% compared to LivaNova PLC's net margin of -2201.34%. LivaNova PLC's return on equity of -18.12% beat VolitionRX's return on equity of --.

LivaNova PLC has a consensus price target of $61.36, signalling upside risk potential of 46.52%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 467.22%. Given that VolitionRX has higher upside potential than LivaNova PLC, analysts believe VolitionRX is more attractive than LivaNova PLC.

LivaNova PLC has a beta of 0.842, which suggesting that the stock is 15.825% less volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

LivaNova PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova PLC pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

LivaNova PLC quarterly revenues are $316.9M, which are larger than VolitionRX quarterly revenues of $246.4K. LivaNova PLC's net income of -$327.3M is lower than VolitionRX's net income of -$5.4M. Notably, LivaNova PLC's price-to-earnings ratio is 38.16x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova PLC is 1.79x versus 35.53x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -103.3% compared to LivaNova PLC's net margin of -2828.67%. LivaNova PLC's return on equity of -18.12% beat Catheter Precision's return on equity of -137.84%.

LivaNova PLC has a consensus price target of $61.36, signalling upside risk potential of 46.52%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 733.68%. Given that Catheter Precision has higher upside potential than LivaNova PLC, analysts believe Catheter Precision is more attractive than LivaNova PLC.

LivaNova PLC has a beta of 0.842, which suggesting that the stock is 15.825% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.870, suggesting its less volatile than the S&P 500 by 187.02%.

LivaNova PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova PLC pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

LivaNova PLC quarterly revenues are $316.9M, which are larger than Catheter Precision quarterly revenues of $143K. LivaNova PLC's net income of -$327.3M is lower than Catheter Precision's net income of -$4M. Notably, LivaNova PLC's price-to-earnings ratio is 38.16x while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova PLC is 1.79x versus 2.76x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -103.3% compared to LivaNova PLC's net margin of 0.18%. LivaNova PLC's return on equity of -18.12% beat Xtant Medical Holdings's return on equity of -26.62%.

LivaNova PLC has a consensus price target of $61.36, signalling upside risk potential of 46.52%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 137.51%. Given that Xtant Medical Holdings has higher upside potential than LivaNova PLC, analysts believe Xtant Medical Holdings is more attractive than LivaNova PLC.

LivaNova PLC has a beta of 0.842, which suggesting that the stock is 15.825% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

LivaNova PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LivaNova PLC pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

LivaNova PLC quarterly revenues are $316.9M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. LivaNova PLC's net income of -$327.3M is lower than Xtant Medical Holdings's net income of $58K. Notably, LivaNova PLC's price-to-earnings ratio is 38.16x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LivaNova PLC is 1.79x versus 0.83x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.